Allogene Therapeutics Prices $175M Public Offering Following Positive Clinical Trial Results

summarizeSummary

Allogene Therapeutics has priced an underwritten public offering of 87.5 million shares at $2.00 per share, raising $175 million in gross proceeds to fund its operations and clinical development following recent positive trial data.

check_boxKey Events

• Public Offering Priced

  Allogene Therapeutics priced an underwritten public offering of 87.5 million shares of common stock at $2.00 per share, generating $175 million in gross proceeds.

• Significant Capital Raise

  The company expects to receive approximately $163.9 million in net proceeds, which will be allocated to general corporate purposes, including clinical trial expenses and research and development.

• Substantial Dilution for Shareholders

  The offering introduces significant dilution, with new investors experiencing an immediate dilution of $0.56 per share in net tangible book value. The 87.5 million new shares represent approximately 38.14% dilution relative to shares outstanding as of December 31, 2025.

• Strategic Timing Post-Clinical Data

  This capital raise follows closely on the heels of highly positive interim futility analysis results from the pivotal Phase 2 ALPHA3 trial for cema-cel, allowing the company to strengthen its balance sheet from a position of clinical progress.

auto_awesomeAnalysis

This 424B5 filing finalizes the terms and pricing of a significant public offering, which was initially proposed on April 13, 2026. The offering, priced at a discount to recent trading, is strategically timed to capitalize on the highly positive interim Phase 2 ALPHA3 trial results announced just days prior. While the issuance of 87.5 million new shares will result in substantial dilution for existing shareholders, the $163.9 million in net proceeds provides a critical capital infusion for Allogene Therapeutics. This funding is essential for advancing its clinical pipeline, including the cema-cel program, and extends the company's cash runway, mitigating near-term financing risks for this clinical-stage biotech.